title: The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.
abstract: CONCLUSIONS
  Exochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena.
  
  
  BACKGROUND
  In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation.
  
  
  RESULTS
  To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions.
  
  
  CONCLUSIONS
  Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.
authors.affiliation: 1 Division of Cardiology, Department of Medicine, University of Colorado Health Sciences Center , Denver, Colorado.
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Horwitz
authors.forename: Marcus A
authors.initials: MA
authors.lastname: Horwitz
mesh_terms: D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy*; D009161:Mycobacterium / Q000378:metabolism; D009169:Mycobacterium tuberculosis / Q000378:metabolism*; D010456:Peptides, Cyclic / Q000378:metabolism / Q000627:therapeutic use*; D017262:Siderophores / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D007502:Iron Chelating Agents; D010456:Peptides, Cyclic; D017262:Siderophores; C010953:exochelins